close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

476.71 +7.44 (+1.59%)
Streaming Delayed Price Updated: 3:23 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
News headline image
The Gene‑Therapy Breakthrough Story You'll Be Mad You Ignored at These Prices ↗
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now. 
Via The Motley Fool
Topics ETFs
News headline image
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows ↗
Via MarketBeat
News headline image
5 Insightful Analyst Questions From Vertex Pharmaceuticals’s Q4 Earnings Call
Vertex Pharmaceuticals delivered fourth quarter results that outpaced Wall Street's revenue expectations, driven by continued expansion in cystic fibrosis therapies and early contributions from... 
Via StockStory
Topics Earnings
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Posts Mixed Q4 2025 Results, Provides 2026 Guidance ↗
Via Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Growth and Breakout Opportunity ↗
Via Chartmill
News headline image
1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
News headline image
Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash ↗
Vertex has the revenue power to excel during any market environment. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
In a move that could reshape the multi-billion-dollar retinal disease market, French pharmaceutical giant Sanofi (NASDAQ: SNY) has reportedly returned to the negotiating table with a significantly... 
Via MarketMinute
News headline image
Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
News headline image
The Blastoff-Ready Biotech Stock You'll Kick Yourself for Not Buying in 2026 ↗
2026 could be a big year for this company. 
Via The Motley Fool
Top S&P500 movers in Friday's session ↗
Via Chartmill
News headline image
Why CRISPR Therapeutics Stock Is Up Today (Despite Its Q4 Earnings Miss) ↗
A sales partner offered a ray of hope that this company couldn't for itself. 
Via The Motley Fool
Friday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation
As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,... 
Via MarketMinute
Topics Artificial Intelligence ETFs Government
News headline image
VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 9.5% year on year to $3.19 billion. The company expects the full... 
Via StockStory
News headline image
Vertex (VRTX) Q4 2025 Earnings Call Transcript ↗
Vertex (VRTX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 9.5% year on year to $3.19 billion. The company expects the full... 
Via StockStory
News headline image
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals (VRTX) Q4 Earnings: What To Expect
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell ↗
Vertex stock has climbed more than 60% over three years. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Buy Vertex Before Feb. 12? ↗
Biotech Vertex, known for its cystic fibrosis therapies, is set to report earnings on Feb. 12 
Via The Motley Fool
Topics Intellectual Property
News headline image
Provident Dumps 490,000 MapleBear Shares Worth $18 Million ↗
Maplebear Inc. connects North American households with personal shoppers through its technology-driven grocery delivery platform. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Should You Buy Vertex Pharmaceuticals Before Feb. 12? ↗
The next 12 months will be important for the drugmaker. 
Via The Motley Fool
News headline image
The Bond Market Is Flashing a Clear Warning About the Fed: 3 Stocks to Buy ↗
The bond market is speaking more loudly than the stock market about the likely direction of the Federal Reserve. 
Via The Motley Fool
Topics Bonds Economy Government
News headline image
2 Top Healthcare Stocks to Buy in February ↗
There's a bright future ahead for both, but it's important to be patient. 
Via The Motley Fool
Topics World Trade
News headline image
The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
3 Market-Beating Stocks Worth Investigating
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
News headline image
Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals ↗
The biotech could be on the verge of expanding its lineup and entering a new era of growth. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today